Formosa gets rights to Medvisis’ treatment for pain after ocular surgery
APP13007 (clobetasol propionate) is intended for the treatment of post-operative inflammation and pain after ocular surgery and is derived from Formosa Pharma’s unique APNT nanoparticle formulation platform
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry